Dentsply Sirona and Biolase are both medical companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, profitability, valuation, risk, dividends and earnings. Dentsply Sirona presently has a consensus target price of $67.00, indicating a potential upside of 33.09%.
No comments:
Post a Comment